GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nightstar Therapeutics PLC (NAS:NITE) » Definitions » Price-to-Operating-Cash-Flow

Nightstar Therapeutics (Nightstar Therapeutics) Price-to-Operating-Cash-Flow : (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nightstar Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-04-25), Nightstar Therapeutics's share price is $25.41. Nightstar Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2019 was $-1.57. Hence, Nightstar Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Nightstar Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

NITE's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 24.7
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Nightstar Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2019 was $-0.35. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2019 was $-1.57.


Nightstar Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Nightstar Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nightstar Therapeutics Price-to-Operating-Cash-Flow Chart

Nightstar Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18
Price-to-Operating-Cash-Flow
- - - -

Nightstar Therapeutics Quarterly Data
Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nightstar Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Nightstar Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nightstar Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nightstar Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Nightstar Therapeutics's Price-to-Operating-Cash-Flow falls into.



Nightstar Therapeutics Price-to-Operating-Cash-Flow Calculation

Nightstar Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=25.41/-1.566
=

Nightstar Therapeutics's Share Price of today is $25.41.
Nightstar Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.57.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Nightstar Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Nightstar Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Nightstar Therapeutics (Nightstar Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
215 Euston Road, London, GBR, NW1 2BE
Nightstar Therapeutics Ltd is a clinical-stage gene therapy company. It is focused on developing and commercializing a pipeline of novel and potentially curative, one-time retinal gene therapies for patients suffering from rare inherited retinal diseases. The company's retinal gene therapy product candidate, NSR-REP1, is being developed for the treatment of choroideremia, a rare, degenerative, X-linked genetic retinal disorder primarily affecting males that is caused by a mutation in the CHM gene.
Executives
Nea 15 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Gregory Scott Robinson officer: Chief Scientific Officer NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
James G Mcarthur director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram officer: Chief Financial Officer NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Tuyen Ong officer: Chief Development Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Paula K Cobb director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott M Whitcup director 2525 DUPONT DRIVE, IRVINE CA 92612
Scott D Sandell 10 percent owner
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett 10 percent owner